NO20022065L - Terapeutisk anvendelse - Google Patents

Terapeutisk anvendelse

Info

Publication number
NO20022065L
NO20022065L NO20022065A NO20022065A NO20022065L NO 20022065 L NO20022065 L NO 20022065L NO 20022065 A NO20022065 A NO 20022065A NO 20022065 A NO20022065 A NO 20022065A NO 20022065 L NO20022065 L NO 20022065L
Authority
NO
Norway
Prior art keywords
therapeutic use
patient
chemoprevention
onset
effective amount
Prior art date
Application number
NO20022065A
Other languages
English (en)
Other versions
NO323206B1 (no
NO20022065D0 (no
Inventor
Nigel James Bundred
Original Assignee
Univ Manchester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Manchester filed Critical Univ Manchester
Publication of NO20022065D0 publication Critical patent/NO20022065D0/no
Publication of NO20022065L publication Critical patent/NO20022065L/no
Publication of NO323206B1 publication Critical patent/NO323206B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20022065A 1999-11-02 2002-04-30 Anvendelse av EGFR-tyrosinkinase-inhibitor for fremstilling av et medikament, og et medisinsk testsett som omfatter en EGFR-tyrosinkinase-inhibitor NO323206B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9925958.2A GB9925958D0 (en) 1999-11-02 1999-11-02 Therapeutic use
PCT/GB2000/004190 WO2001032155A2 (en) 1999-11-02 2000-11-01 Use of egfr tyrosine kinase inhibitors for treating breast cancer

Publications (3)

Publication Number Publication Date
NO20022065D0 NO20022065D0 (no) 2002-04-30
NO20022065L true NO20022065L (no) 2002-06-24
NO323206B1 NO323206B1 (no) 2007-01-22

Family

ID=10863835

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20022065A NO323206B1 (no) 1999-11-02 2002-04-30 Anvendelse av EGFR-tyrosinkinase-inhibitor for fremstilling av et medikament, og et medisinsk testsett som omfatter en EGFR-tyrosinkinase-inhibitor

Country Status (21)

Country Link
US (1) US7553815B1 (no)
EP (1) EP1272188B1 (no)
JP (1) JP2003513035A (no)
KR (1) KR100785359B1 (no)
CN (1) CN1197577C (no)
AT (1) ATE339957T1 (no)
AU (1) AU779190B2 (no)
BR (1) BR0015194A (no)
CA (1) CA2389411C (no)
CY (1) CY1106285T1 (no)
DE (1) DE60030889T2 (no)
DK (1) DK1272188T3 (no)
ES (1) ES2275556T3 (no)
GB (1) GB9925958D0 (no)
IL (1) IL149176A0 (no)
MX (1) MXPA02004272A (no)
NO (1) NO323206B1 (no)
NZ (1) NZ518696A (no)
PT (1) PT1272188E (no)
WO (1) WO2001032155A2 (no)
ZA (1) ZA200203431B (no)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
WO2001089566A1 (en) 2000-05-19 2001-11-29 Genentech, Inc. Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
US7132427B2 (en) 2001-06-21 2006-11-07 Ariad Pharmaceuticals, Inc. Quinazolines and uses thereof
US6872715B2 (en) * 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
US20050038048A1 (en) * 2001-10-29 2005-02-17 Ball Howard Ashley Use of 7h-pyrrollo{2,3-d}pyrimidine derivatives in the treatment of solid tumor diseases
EP2305255B1 (en) * 2001-12-03 2012-08-22 Bayer HealthCare LLC Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
US7078409B2 (en) 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
SI1509230T1 (sl) * 2002-06-05 2007-06-30 Cedars Sinai Medical Center Gefitinib (iressa) za zdravljenje raka
EP1664716A4 (en) * 2003-08-15 2008-08-13 Smithkline Beecham Corp CANCER BIOMARKERS
BRPI0414532B1 (pt) 2003-09-19 2018-06-05 Astrazeneca Ab Composto derivado de quinazolina, processo para preparar 0 mesmo, composição farmaceutica, e, uso de um composto derivado de quinazolina
WO2005039588A2 (en) * 2003-10-22 2005-05-06 Novartis Ag Methods for determining the risk of developing liver and lung toxicity
US7701341B2 (en) * 2004-09-01 2010-04-20 Microsoft Corporation Device service provider interface
EP3698807A1 (en) 2005-01-21 2020-08-26 Genentech, Inc. Fixed dosing of her antibodies
RS53128B (sr) 2005-02-23 2014-06-30 Genentech Inc. Produžavanje vremena progresije bolesti ili preživljavanja kod pacijenata obolelih od kancera jajnika korišćenjem pertuzumaba
CN101003514A (zh) 2006-01-20 2007-07-25 上海艾力斯医药科技有限公司 喹唑啉衍生物、其制备方法及用途
EP1982718A4 (en) 2006-02-09 2010-05-12 Daiichi Sankyo Co Ltd PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OF CANCER
CN1899616A (zh) * 2006-07-20 2007-01-24 中国人民解放军军事医学科学院生物工程研究所 非受体酪氨酸激酶c－Abl特异性抑制剂的新用途
MX2009008981A (es) 2007-03-02 2009-09-02 Genentech Inc Prediccion de respuesta a un inhibidor her.
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
WO2008154249A2 (en) 2007-06-08 2008-12-18 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
MA33091B1 (fr) 2009-03-11 2012-03-01 Ardea Biosciences Inc Combinaisons pharmaceutiques comprenant rdea119/bay 869766 pour le traitement de cancers specifiques
KR20150036824A (ko) 2009-03-20 2015-04-07 제넨테크, 인크. 이중특이적 항-ｈｅｒ 항체
US20120121586A1 (en) 2009-05-29 2012-05-17 Astrid Kiermaier Modulators for her2 signaling in her2 expressing patients with gastric cancer
ES2519348T3 (es) 2010-02-18 2014-11-06 Genentech, Inc. Antagonistas de neurregulina y uso de los mismos en el tratamiento del cáncer
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
WO2012069466A1 (en) 2010-11-24 2012-05-31 Novartis Ag Multispecific molecules
EP2655413B1 (en) 2010-12-23 2019-01-16 F.Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
BR112014003431A2 (pt) 2011-08-17 2017-06-13 Genentech Inc anticorpo, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, agente farmacêutico, uso do anticorpo, método de tratamento de um indivíduo que tem câncer e método de aumento de tempo para recorrência de tumor
WO2013063229A1 (en) 2011-10-25 2013-05-02 The Regents Of The University Of Michigan Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells
AU2012346540C1 (en) 2011-11-30 2019-07-04 Genentech, Inc. ErbB3 mutations in cancer
WO2013083810A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
WO2013148315A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
RU2692773C2 (ru) 2012-11-30 2019-06-27 Ф.Хоффманн-Ля Рош Аг Идентификация пациентов, нуждающихся в совместной терапии с использованием ингибитора pd-l1
US20190151346A1 (en) 2016-05-10 2019-05-23 INSERM (Institute National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US5795910A (en) * 1994-10-28 1998-08-18 Cor Therapeutics, Inc. Method and compositions for inhibiting protein kinases
ATE446955T1 (de) * 1995-03-30 2009-11-15 Pfizer Prod Inc Chinazolinone derivate
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
CA2223081C (en) * 1995-06-07 2001-03-06 Pfizer Inc. Heterocyclic ring-fused pyrimidine derivatives
PL188959B1 (pl) 1995-07-06 2005-05-31 Novartis Ag Pirolopirymidyny i sposoby ich wytwarzania
AU4079999A (en) * 1998-05-15 1999-12-06 Imclone Systems Incorporated Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
EP2059902B1 (en) 2006-08-28 2010-04-07 Koninklijke Philips Electronics N.V. Method and apparatus for image enhancement

Also Published As

Publication number Publication date
DK1272188T3 (da) 2007-01-29
EP1272188A2 (en) 2003-01-08
AU1155901A (en) 2001-05-14
KR20020064306A (ko) 2002-08-07
GB9925958D0 (en) 1999-12-29
DE60030889T2 (de) 2007-04-05
PT1272188E (pt) 2007-01-31
ZA200203431B (en) 2003-02-26
WO2001032155A2 (en) 2001-05-10
ATE339957T1 (de) 2006-10-15
JP2003513035A (ja) 2003-04-08
WO2001032155A3 (en) 2002-05-10
NO323206B1 (no) 2007-01-22
US7553815B1 (en) 2009-06-30
IL149176A0 (en) 2002-11-10
NZ518696A (en) 2004-12-24
CA2389411C (en) 2009-09-01
AU779190B2 (en) 2005-01-13
DE60030889D1 (de) 2006-11-02
CY1106285T1 (el) 2011-10-12
NO20022065D0 (no) 2002-04-30
KR100785359B1 (ko) 2007-12-18
CN1197577C (zh) 2005-04-20
ES2275556T3 (es) 2007-06-16
CA2389411A1 (en) 2001-05-10
CN1387437A (zh) 2002-12-25
BR0015194A (pt) 2002-06-18
EP1272188B1 (en) 2006-09-20
MXPA02004272A (es) 2003-08-20

Similar Documents

Publication Publication Date Title
NO20022065D0 (no) Terapeutisk anvendelse
TR200201442T2 (tr) Ağrı hafifletme, kemik kanseri terapisi ve kemik yüzeyinin sağlıklı tutulması için kireçlenmiş hedef dokulara yönelik radyum-223 hazırlanması ve kullanımı.
DK1565471T3 (da) Quionolinylpyrazoler
ATE307601T1 (de) Brustkrebsbehandlung mittels natürlicher ätherischer öle
PT1223980E (pt) Utilizacao de inibidores de csf-1
CY1112753T1 (el) Θεραπευτικη αγωγη καρκινων του ανθρωπινου σωματος με τη χρηση toy ετ743
MY138059A (en) Use of ikb-kinase inhibitors in pain therapy
NO20032027D0 (no) Effektive antitumorbehandlinger
PT1390371E (pt) Oxazolo- e furopirimidinas e sua utilizacao em medicamentos contra tumores
SE9802208D0 (sv) Novel compounds
ATE313334T1 (de) Behandlung von tumoren mit photodynamischer therapie
ATE297751T1 (de) Kombinationstherapie mit keratinozyten- wachstumfaktor und ein epidermis-wachstumfaktor inhibitor
SE9802209D0 (sv) Novel compounds
SE9902597D0 (sv) New use
MX2007006927A (es) Combinacion de inhibidor de tirosina cinasa y her-2/neu para terapia de cancer.
GEP201606538B (en) Preoperative treatment of post operative pain
ATE330600T1 (de) Kombinationspräparat zur krebstherapie
PL367707A1 (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
IT1320192B1 (it) Composizione terapeutica per la cura della psoriasi.
DK1150981T3 (da) Terapeutisk necleosidforbindelse
DE60234995D1 (de) Tatakrebs
DE60316927D1 (de) Verwendung von devazepide als schmerzmittel
EA200600987A1 (ru) Применение сирамезина в лечении злокачественных опухолей
UA37750A (uk) Спосіб лікування запальних захворювань пародонту у вагітних жінок

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees